Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
ANG Lifesciences India's 3-Year RORE % for the quarter that ended in Mar. 2026 was 2.78%.
The industry rank for ANG Lifesciences India's 3-Year RORE % or its related term are showing as below:
BOM:540694's 3-Year RORE % is ranked worse than 50.26% of 945
companies
in the Drug Manufacturers industry
Industry Median: 3
vs BOM:540694: 2.78
ANG Lifesciences India (BOM:540694) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
ANG Lifesciences India 3-Year RORE % Related Terms
ANG Lifesciences India 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANG Lifesciences India 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where ANG Lifesciences India's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
ANG Lifesciences India (BOM:540694) has a 3-Year RORE % of 2.78 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ANG Lifesciences India and its competitors. According to the industry distribution chart, ANG Lifesciences India ranks #475 out of 945 companies in the Drug Manufacturers industry, placing it in the top 50.3%.
Is ANG Lifesciences India's 3-Year RORE % too high?
ANG Lifesciences India's current 3-Year RORE % is 2.78. The Drug Manufacturers industry median 3-Year RORE % is 3.00. ANG Lifesciences India's value of 2.78 is 7.3% below this industry median. Based on the distribution chart, ANG Lifesciences India ranks #475 out of 945 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ANG Lifesciences India has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's 3-Year RORE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ANG Lifesciences India ranks #475 out of 945 companies for 3-Year RORE %. This places ANG Lifesciences India in the lower half of its industry. The industry median 3-Year RORE % is 3.00. ANG Lifesciences India's value of 2.78 is 7.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.00, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANG Lifesciences India's current 3-Year RORE % of 2.78 is 7.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ANG Lifesciences India and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANG Lifesciences India's current 3-Year RORE % is 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Fairly Valued. The stock's GF Value™ is ₹30.13, compared to a current price of ₹30.60 — trading 1.6% above its estimated fair value. The current 3-Year RORE % is 2.78 and 7.3% below the Drug Manufacturers industry median of 3.00. ANG Lifesciences India's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current 3-Year RORE % is 2.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?
Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued.
The current stock price of ₹30.60 is trading 1.6% above its estimated GF Value™ of ₹30.13.
GuruFocus considers ANG Lifesciences India to be Fairly Valued.
Key valuation signals for BOM:540694:
3-Year RORE %: 2.78
GF Value™: ₹30.13 vs. price of ₹30.60 (1.6% above fair value)
Industry Position: 7.3% below the Drug Manufacturers median (#475 of 945)
No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
63GF Score
Get the complete analysis for BOM:540694
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540694 has been successfully added to your 
